Solaris Resources Inc. (CVE:SLS – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for Solaris Resources in a research note issued to investors on Monday, August 10th. HC Wainwright analyst H. Ihle now anticipates that the company will earn ($0.20) per share for the year, up from their prior estimate of ($0.47).
Solaris Resources Stock Performance
CVE:SLS opened at C$6.15 on Wednesday. Solaris Resources has a 52 week low of C$1.38 and a 52 week high of C$7.09. The stock’s 50-day moving average price is C$6.15 and its 200-day moving average price is C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.
Featured Articles
- Five stocks we like better than Solaris Resources
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
